Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases in the United States. The company's lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. It also provides ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York. Show more

Location: 630 5th Avenue, New York, NY, 10111, United States | Website: https://www.anavex.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

948.5M

52 Wk Range

$4.93 - $14.44

Previous Close

$11.18

Open

$11.18

Volume

882,831

Day Range

$10.87 - $11.18

Enterprise Value

671.4M

Cash

115.8M

Avg Qtr Burn

-7.454M

Insider Ownership

3.33%

Institutional Own.

37.67%

Qtr Updated

03/31/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ANAVEX 2-73 (blarcamesine) (RS-002) Details Rett syndrome	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ANAVEX 2-73 (Blarcamesine) Details Parkinson's disease	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ANAVEX 2-73 (Blarcamesine) Details Alzheimer's disease	Phase 2/3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ANAVEX 2-73 (blarcamesine) (2-73-RS-003) Details Rett syndrome	Phase 2/3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ANAVEX 2-73 (blarcamesine) Details Fragile X syndrome	Phase 2/3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ANAVEX 3-71 (AF710B) Details Schizophrenia	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.